Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Prepaid Assets (2022 - 2025)

Oramed Pharmaceuticals' Prepaid Assets history spans 4 years, with the latest figure at $2.7 million for Q4 2025.

  • For Q4 2025, Prepaid Assets changed N/A year-over-year to $2.7 million; the TTM value through Dec 2025 reached $2.7 million, changed N/A, while the annual FY2025 figure was $2.7 million, N/A changed from the prior year.
  • Prepaid Assets reached $2.7 million in Q4 2025 per ORMP's latest filing, up from $1.4 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $2.7 million in Q4 2025 to a low of $474000.0 in Q3 2024.
  • Average Prepaid Assets over 4 years is $1.1 million, with a median of $832000.0 recorded in 2025.
  • Peak YoY movement for Prepaid Assets: tumbled 64.79% in 2024, then surged 201.69% in 2025.
  • A 4-year view of Prepaid Assets shows it stood at $1.4 million in 2022, then tumbled by 61.34% to $537000.0 in 2023, then dropped by 11.73% to $474000.0 in 2024, then soared by 478.27% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Prepaid Assets are $2.7 million (Q4 2025), $1.4 million (Q3 2025), and $1.1 million (Q2 2025).